Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention (NCT03279952), a na phase 4 study. The primary outcome is Change in Parent Rated Irritability on the IOWA Connor Irritability Score From Baseline to 6 Weeks..

2. Clinical Question

The study’s framing reflects interest in irritability as a concern that may occur alongside ADHD and may not simply track ADHD symptom severity. The registry description notes that response to CNS stimulants can vary, and identifies uncertainty about mechanisms behind that variation. Those points motivate studying change in irritability, but they do not establish what happened to participants in this study.

Because the study has one group, any change from baseline would describe the observed course in that group. Without a comparator, such a change could not by itself distinguish an intervention effect from other explanations, such as natural variation or changes over time. The primary result needed to assess even that within-group course is not reported in the registry record.

3. Trial Design

The registry describes a phase 4, single-group study with no masking and no randomized allocation. The intervention is a CNS stimulant, and the study condition is ADHD. The record lists enrollment of 11 and a status of terminated. The study start is recorded as 2018-06-01, and primary completion as 2024-06-30.

Nine patients completed the study. For the primary outcome, the registry says data were missing for one patient, leaving eight patients in that outcome analysis. These figures describe different stages of study participation and outcome availability; they should not be treated as interchangeable denominators. The record does not explain why some participants did not complete the study or why the primary outcome was missing for one patient.

The primary outcome compares parent-rated irritability at baseline and 6 weeks. The listed intervention does not specify a particular CNS stimulant, dose, or treatment regimen. Further details about eligibility, recruitment, treatment delivery, follow-up procedures, or reasons for termination are not reported in the registry record.

There is no randomized control arm or other comparator in the design described. Consequently, the design can address how the recorded measure changed within the study group only if results are available; it cannot estimate a treatment contrast against a concurrent control group. No primary outcome estimate or statistical analysis is posted in the registry record, so the amount and direction of any within-group change are unknown from this record.

The record lists secondary outcomes concerning impairment, aggression, callous-unemotional traits, affective reactivity, and side effects. The registry identifies eight outcome measures, but does not provide analysis results for them. A detailed protocol, statistical analysis plan, or explanation of the terminated status is not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Nine patients completed the study. However, data for this outcome was missing for one patient, so the outcome was analyzed for eight patients.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change in Parent Rated Irritability on the IOWA Connor Irritability Score From Baseline to 6 Weeks., measured over Baseline and 6 weeks.

The primary endpoint is change in parent-rated irritability on the IOWA Connor Irritability Score from baseline to 6 weeks. The registry describes a parent rating of symptoms using three items, each rated from 0 to 3. The total score ranges from 0-9, with higher scores indicating more irritability. The score is a continuous measure, and the registry identifies the summary parameter as a mean with standard deviation.

Parent ratings are used to capture a caregiver’s assessment of the child’s symptoms. In general, repeated measurement can describe whether a rating differs between an initial assessment and a later assessment. The chosen interval is baseline and 6 weeks; the registry does not report the observed scores at either assessment or the mean change between them.

The endpoint is relevant to the stated study focus because it measures irritability rather than ADHD symptoms generally. The record’s description distinguishes irritability from simply having more severe ADHD symptoms and identifies irritability as a treatment-related concern. This rationale explains the choice of measure, but it does not establish that the scale changed in this study or that any change was meaningful.

The score’s range and direction help interpret a reported result: higher values indicate more irritability. However, the registry record does not report a result, standard deviation, confidence interval, or p-value for this endpoint. It also does not report a threshold for a clinically important change. Thus, the endpoint is defined, but its observed magnitude, precision, and clinical interpretation cannot be determined from the posted record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes the primary outcome as a continuous measure summarized by a mean and standard deviation. A mean gives a measure of the average score or change in a group. A standard deviation describes how spread out individual observations are around that average. These are different quantities: the mean summarizes the group’s central value, while the standard deviation describes variation among observations.

What does a baseline-to-follow-up change represent?

In general, a within-person change compares the same participant’s measurement at an earlier and later assessment. A group summary of those changes can describe the average course among participants with the needed measurements. The primary outcome is defined over baseline and 6 weeks, but the registry record does not give baseline values, follow-up values, or a mean change. It is therefore not possible to examine the numerical change or its variability.

For a continuous outcome, uncertainty around an estimate is often expressed with a confidence interval. In general, a confidence interval describes a range of values compatible with the data and the statistical procedure used; it is not a guarantee that the true value lies inside that particular interval. No confidence interval is reported for the primary outcome. A p-value, which under a specified model measures how unusual data would be under a null hypothesis, is also not reported. Neither can be reconstructed from the information in the registry record without inventing or calculating results.

What does the single-group design permit?

In general, a single-group pre-post study can describe change over time among participants who have measurements at both assessments. It lacks a concurrent control group that would show what happened over the same period without the intervention or under another intervention. Consequently, observed change alone cannot isolate the effect of treatment from time trends, measurement variation, or other influences. This is a design limitation, not a conclusion about the direction of the outcome.

The registry lists no randomized allocation and identifies the model as single-group. It also lists no masking. These design details mean there is no randomized treatment contrast and no masking procedure reported. They do not establish how ratings were collected beyond the stated parent-rated outcome, or whether anyone involved in assessment knew treatment details; further information is not reported in the registry record.

How should the planning assumptions be read?

The registry’s sample-size assumptions describe a planning illustration based on an observed effect, rather than the study’s own design. The assumptions specify a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is described as a stated fraction of the observed effect. Those are hypothetical planning inputs and should not be mistaken for features of this single-group study.

In general, sample-size planning asks how many participants per arm would be needed to detect a chosen effect under specified assumptions about variability, significance level, and power. Such calculations are not observed power and do not show that a study actually had adequate power. They are planning illustrations, not evidence about the intervention’s result. The registry record does not report the numerical planning outputs or the observed effect used in the illustration, so those quantities cannot be assessed.

General statistical methods can also be sensitive to distributional assumptions. A normal approximation is a simplifying approach for some calculations; with limited data, the adequacy of an approximation can be difficult to evaluate. Over-dispersion, in general, means that variability exceeds what a model expects, and can make standard errors too small if not addressed. The registry record does not report a model fit, a dispersion assessment, or a detailed method for analyzing the primary outcome. No claim can be made about whether these issues were tested or how they were handled.

What analysis details are missing?

The record identifies the primary outcome as a mean with standard deviation, but does not report the exact statistical test or model, whether the analysis used raw scores or change scores, how any assumptions were assessed, or how missing outcome data were handled. It also does not report an adjustment strategy, a confidence level for intervals, or an analysis plan. These items are not recoverable from the outcome definition alone and are not reported in the registry record.

The number of outcome measures is listed as eight, and the record lists multiple secondary outcomes. Multiple outcomes can raise a multiplicity question: when several hypotheses are tested, the chance of at least one false-positive finding can increase if tests are considered together without adjustment. This is a general concern, not a claim that a particular adjustment was or was not applied in the study. The registry record does not report a multiplicity strategy or outcome-specific statistical analyses.

Because no analysis results are posted, there is no sponsor analysis to compare with a recalculation. No recalculated effect estimate or planning value should be interpreted as an observed result. The available methodological information supports a description of the outcome and design, but not an independent assessment of the primary endpoint’s estimated effect or statistical uncertainty.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Medication Arm")
n   <- c(8)
m   <- c(3.13)
sp  <- c(2.53)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Medication Arm  8  3.130  2.530  1.015  5.245

11. Multiplicity, Missing Data and Analysis Populations

The registry lists eight outcome measures and includes secondary outcomes for parent-rated impairment, aggression, callous-unemotional traits, affective reactivity, and side effects. Considering several outcomes can create a multiplicity issue. In general, if many statistical tests are performed, the chance of finding at least one apparently notable result by chance may rise. Researchers may address this through a prespecified hierarchy or an adjustment method, but the registry record does not report a multiplicity plan.

The record lists zero analyses. It does not post estimates, tests, or outcome-specific results for the primary or secondary measures. The statistical analysis plan, including any planned outcome hierarchy, is not reported in the registry record. Therefore, there is no basis for determining whether multiplicity was controlled or how the results were intended to be interpreted across outcomes.

For the primary endpoint, the registry states that one patient’s outcome data were missing and that the outcome was analyzed for eight patients. Nine patients completed the study, while enrollment is listed as 11. Reasons for missing outcome data and non-completion are not reported in the registry record. The record does not state whether the analysis used only available cases, imputation, or another approach, nor whether sensitivity analyses were performed.

In general, missing data can affect an estimate when the likelihood of missingness is related to participant characteristics or outcomes. The direction and size of any such effect depend on circumstances that are not described. The record does not specify an analysis population beyond the stated count for the primary outcome, so broader claims about inclusion or exclusions are not warranted. No results are available to assess whether the missing observation changed the interpretation.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry’s adverse-event figures list 9 participants at risk for serious adverse events and 0 with a serious adverse event. For other adverse events, the record lists 9 at risk and 0 affected. Deaths are listed as 0. These are the reported counts for the medication arm; they are not comparative estimates because no control group is listed.

Zero recorded events means that no events are entered in these registry fields for the stated group. It does not prove that the intervention has no risks, and it does not show that all possible events were absent. The record does not provide event definitions, individual event narratives, exposure duration, or details on how adverse events were collected. The listed follow-up and primary outcome timeframe is baseline and 6 weeks, but the record does not clarify whether safety ascertainment covered exactly that period.

The counts should be read as descriptive registry data, not as a complete safety assessment. With no comparator and no reported statistical analysis of safety, the figures cannot establish a relative safety difference or rule out uncommon harms. The record’s terminated status does not explain why the study stopped and should not be interpreted as evidence about safety.

13. What the Result Does, and Does Not, Mean

The record establishes that the study asked whether parent-rated irritability changed from baseline to 6 weeks among patients receiving a CNS stimulant. It defines the IOWA Connor Irritability Score and identifies the outcome analysis population as eight patients. It also describes a single-group, unmasked design and reports the study as terminated.

It does not establish whether irritability scores increased, decreased, or stayed similar. No primary outcome estimate, standard deviation, confidence interval, or p-value is reported in the registry record. Thus, the central statistical result needed to characterize the observed change is unavailable. The study’s motivation and endpoint definition cannot substitute for outcome data.

Even if a within-group change were available, the single-group design would not show how that change compares with what would have happened in a control group. It would describe the group’s course over time, while leaving alternative explanations unresolved. The design therefore does not support a causal estimate against another treatment or no treatment.

The absence of a reported result is not evidence that there was no effect, nor evidence of benefit or harm. Likewise, zero adverse events entered in the listed safety fields does not establish that no risks exist. The record does not explain the terminated status, so it cannot be used to infer the reason the study ended.

The most defensible conclusion is limited: the registry documents a study of a parent-rated irritability outcome with incomplete outcome availability and no posted analysis results. It does not permit a conclusion about the size, direction, precision, clinical importance, or causal interpretation of the outcome.

14. Why This Trial Matters Statistically

This study raises a useful statistical question: how should irritability be measured and followed when studying patients with ADHD who receive a CNS stimulant? The registry separates parent-rated irritability from ADHD symptom severity in its background rationale and identifies irritability as the primary outcome. That focus illustrates why choosing an outcome aligned with the research question matters: a study aimed at irritability needs a measure that directly captures irritability rather than relying only on a broader diagnosis or symptom domain.

The record also illustrates how design affects the claims that can be made. A single-group before-and-after study can describe change among observed participants, but without a comparator it cannot distinguish intervention-associated change from other explanations. This distinction is central to reading statistical results: a numerical change, even if reported, is not automatically a treatment effect.

Missing outcome data and limited analysis information also shape interpretability. The registry reports an outcome analysis for eight patients, with one missing outcome among those who completed the study, but does not explain missingness or analysis handling. These details affect how readers judge the population represented by an estimate and how robust a result might be.

Finally, a defined endpoint is not the same as a reported finding. The registry provides the scale’s interpretation and timing, but no numerical outcome result. This makes the record a case in the difference between a research question, a study design, and evidence answering the question. Each is informative, but only the last requires reported outcome data with enough statistical detail to assess magnitude and uncertainty.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpretation is that the primary outcome result is not reported in the registry record. Without a mean change, measure of variability, or uncertainty interval, readers cannot assess the observed direction, magnitude, or precision of change. The record also does not provide a threshold for clinically important change.

The design is single-group and has no randomized comparator. Any reported baseline-to-follow-up change would therefore be descriptive rather than a controlled treatment contrast. No masking is listed. Further details about how parent ratings were obtained or whether assessment procedures were standardized are not reported in the registry record.

Outcome availability is incomplete: the registry states that the primary outcome was analyzed for eight patients because data were missing for one patient, while nine patients completed the study and enrollment is listed as 11. The reasons for missing data and non-completion are not reported. The record does not describe missing-data methods or sensitivity analyses, so the impact of unavailable observations cannot be evaluated.

The specific CNS stimulant, dose, and treatment regimen are not reported in the registry record. Participant characteristics beyond the condition and pediatric framing are also not reported, limiting assessment of who the findings might represent even if results were available. The record lists the study as terminated but does not state why.

The analysis plan, statistical model, and multiplicity approach are not reported, while multiple outcome measures are listed. Safety fields record zero serious and zero other adverse events in the group at risk, but details about event collection and ascertainment are not reported. Together, these gaps restrict both efficacy interpretation and safety characterization.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention — NCT03279952.
• Registry record last updated 2025-08-26; status last verified 2025-08.
• Results first posted 2025-08-26.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes a phase 4, single-group study of a CNS stimulant in relation to parent-rated irritability among patients with ADHD. Its primary outcome is change in the IOWA Connor Irritability Score from baseline to 6 weeks. The scale has three parent-rated items, a total range of 0-9, and higher scores indicate more irritability.

Enrollment is listed as 11, nine patients completed the study, and the primary outcome was analyzed for eight because one patient’s outcome data were missing. The study is listed as terminated. No primary or secondary outcome analysis results are reported in the registry record, and the reason for termination is not reported.

The adverse-event fields list zero serious adverse events, zero other adverse events, and zero deaths among the reported group at risk. With no comparator and no posted outcome analysis, the record does not establish a treatment effect or provide a comparative safety assessment.